At the start of this year, I observed that shares of Gilead Sciences, Inc. (NASDAQ ... to take profits on rips here being ...

Maxim downgraded Gilead (GILD) to Hold from Buy. The stock has appreciated significantly following a pullback in the first half of the year, ...

Shares of Gilead Sciences Inc. GILD shed 0.73% to $86.72 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.40% to 5,864.67 ...

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Gilead Sciences (GILD) closed the latest trading ... The HIV and hepatitis C drugmaker's stock has climbed by 5.22% in the past month, exceeding the Medical sector's loss of 4.16% and the S ...

In this piece, we will look at where Gilead Sciences, Inc. (NASDAQ ... and it covered the bank’s thoughts about the stock market and the US economy for September. The other came in October ...

Truist Financial increased their price target on Gilead Sciences from $82.00 to $83.00 and gave the stock a “hold” rating in a report on Thursday, August 15th. Sanford C. Bernstein assumed ...

The most recent guidance for Gilead Sciences (GILD) was reported on August 8, 2024 for the full year 2024. The company provided earnings per share guidance in the range of $3.60 to $3.90 ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.